Compare Cassava Sciences Inc (FLNA) vs United Parcel Service Inc (UPS) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

UPS stock trades at $92.28, down 0.89% amid bearish technical signals and mixed fundamentals. The company maintains strong profitability with 29.66% ROE and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of UPS Secure Commerce and an exclusive TikTok Shop partnership, while facing headwinds from fuel costs and volume pressures. Analyst consensus remains positive with a $118.67 price target representing 29% upside potential.

The investment case balances attractive valuation metrics (P/E 17.5, P/S 0.89) against declining revenue trends and competitive threats. The 7% dividend yield provides income support, but investors face risks from margin compression and Amazon competition. Wall Street sentiment leans bullish despite recent price weakness, with improving domestic margins seen as the key catalyst.